Exclusive License and Collaboration Agreement Sample Contracts

AMENDED AND RESTATED EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT between HUTCHISON MEDIPHARMA LIMITED and ELI LILLY TRADING (SHANGHAI) COMPANY LIMITED and HUTCHISON CHINA MEDITECH LIMITED
Exclusive License and Collaboration Agreement • October 16th, 2015 • Hutchison China MediTech LTD • Pharmaceutical preparations

This Agreement (the “Agreement”), effective as of 8th October 2013 (the “Effective Date”), is entered into by and among (i) Hutchison MediPharma Limited, a Chinese company, organized and existing under the laws of the People’s Republic of China, having a place of business at Building 4, 720 Cai Lun Road, ZJ Hi-Tech Park, Shanghai, PRC (“Hutchison”) and (ii) Eli Lilly and Company, an U.S.A. company, organized and existing under the laws of the State of Indiana, having a place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 U.S.A. (“Lilly”), and (iii) solely for the purposes of Articles 7.11(a), 7.11(b) and 7.11(c), Hutchison China MediTech Limited, a company organized and existing under the laws of the Cayman Islands with its principal offices at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (the “Hutchison Guarantor”). Hutchison and Lilly may be referred to herein individually as a “Party” or collectively as the “Parties.” Reference to a Party shal

AutoNDA by SimpleDocs
THE SYMBOL “[**]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED AMENDED AND RESTATED...
Exclusive License and Collaboration Agreement • May 30th, 2019 • Hutchison China MediTech LTD • Pharmaceutical preparations

This Agreement (the “Agreement”), effective as of 8th October 2013 (the “Effective Date”), is entered into by and among (i) Hutchison MediPharma Limited, a Chinese company, organized and existing under the laws of the People’s Republic of China, having a place of business at Building 4, 720 Cai Lun Road, ZJ Hi-Tech Park, Shanghai, PRC (“Hutchison”) and (ii) Eli Lilly and Company, an U.S.A. company, organized and existing under the laws of the State of Indiana, having a place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 U.S.A. (“Lilly”), and (iii) solely for the purposes of Articles 7.11(a), 7.11(b) and 7.11(c), Hutchison China MediTech Limited, a company organized and existing under the laws of the Cayman Islands with its principal offices at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (the “Hutchison Guarantor”). Hutchison and Lilly may be referred to herein individually as a “Party” or collectively as the “Parties.” Reference to a Party shal

EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT
Exclusive License and Collaboration Agreement • February 28th, 2014 • Mymetics Corp • Biological products, (no disgnostic substances) • New York

This Exclusive License and Collaboration Agreement (this “Agreement”) is entered into as of the 27th day of December, 2013 (the “Effective Date”) by and between RSV Corporation, a corporation organized under the laws of Delaware, with its principal place of business at 7361 Calhoun Place, Suite 510, Rockville, MD 20855, USA (“RSVC”), and Bestewil Holding B.V., a company organized and existing under the laws of the Netherlands, with a principal business address at J.H. Oortweg 21, 2333 CH Leiden, The Netherlands (“BH”).

EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT
Exclusive License and Collaboration Agreement • November 22nd, 2022 • Health Sciences Acquisitions Corp 2 • Surgical & medical instruments & apparatus • New York

This EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT (“Agreement”) is entered into as of June 30, 2022 (the “Effective Date”) by and between Orchestra Biomed, Inc., a Delaware corporation with a principal place of business at 150 Union Square Drive New Hope, PA 18938 (“Orchestra Biomed”), BackBeat Medical, LLC, a Delaware limited liability company and wholly-owned subsidiary of Orchestra Biomed with a principal place of business at 150 Union Square Drive New Hope, PA 18938 (“BackBeat”, together with Orchestra Biomed, “Orchestra”), and Medtronic, Inc., a Minnesota corporation with a principal place of business at 710 Medtronic Parkway, Minneapolis, Minnesota 55432 (“Medtronic”). Orchestra and Medtronic are referred to each as a “Party” or collectively as the “Parties”.

Amended and Restated Exclusive License and Collaboration Agreement
Exclusive License and Collaboration Agreement • May 3rd, 2017 • Cti Biopharma Corp • Pharmaceutical preparations • England and Wales

LES LABORATOIRES SERVIER, a company duly organized and existing under the laws of France, having offices and principal place of business at 50 Rue Carnot, 92284 Suresnes Cedex, France

EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT
Exclusive License and Collaboration Agreement • June 30th, 2016 • Atomera Inc • Semiconductors & related devices • Massachusetts

This Exclusive License and Collaboration Agreement (“Agreement”) is made and entered into this 3rd day of March, 2010 (the “Effective Date”), by and between Mears Technologies, Inc., a Delaware corporation with its principal offices at 1100 Winter Street, Suite 4700, Waltham, MA 02451 (“Licensor”) and K2 Energy Limited, a corporation with its principal offices at Level 2, 27 Macquarie Place, Sydney NSW 2000, Australia (“Licensee”).

EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT
Exclusive License and Collaboration Agreement • March 11th, 2008 • GTX Inc /De/ • Pharmaceutical preparations • Delaware

This Exclusive License and Collaboration Agreement (this “Agreement”) is made and entered into effective as of the Closing Date (defined below) and is entered into by and between Merck & Co., Inc., a corporation organized and existing under the laws of New Jersey (“Merck”), and GTx, Inc., a corporation organized and existing under the laws of Delaware (“GTx”).

THIRD AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT
Exclusive License and Collaboration Agreement • August 9th, 2010 • Intermune Inc • Pharmaceutical preparations

This Third Amendment (this “Amendment”) to the Exclusive License and Collaboration Agreement effective as of October 16, 2006 (“Original Agreement,” as amended by that certain First Amendment effective as of October 16, 2008 (“First Amendment”) and that certain Second Amendment effective as of October 16, 2009 (“Second Amendment”) (the Original Agreement, as amended by the First Amendment and the Second Amendment, the “Agreement”) is made effective as of April 30, 2010 (the “Third Amendment Effective Date”) and entered into by and between Hoffmann-La Roche Inc., a New Jersey corporation located at 340 Kingsland Street, Nutley, New Jersey 07110 (“Roche Nutley”), and F.Hoffmann-La Roche Ltd, a Swiss corporation, with its principal office at Grenzacherstrasse 124, CH-4070 Basel, Switzerland (“Roche Basel”; Roche Nutley and Roche Basel are collectively referred to as “Roche”), on the one hand, and InterMune, Inc., a Delaware corporation with its principal place of business at 3280 Bayshore

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT (INDICATED BY [***]) HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT INVENTIVA S.A. TREATS AS PRIVATE OR CONFIDENTIAL....
Exclusive License and Collaboration Agreement • September 27th, 2022 • Inventiva S.A. • Pharmaceutical preparations

This Exclusive License and Collaboration Agreement (the “Agreement”) is entered into as of September 21, 2022 (the “Effective Date”), by and between Inventiva S.A., a company incorporated under the laws of France, having its principal place of business at 50, rue de Dijon à Daix (21121), France (“Inventiva”), and Chia Tai Tianqing Pharmaceutical Group, Co., Ltd., a limited liability company incorporated and existing under the laws of the People’s Republic of China, having its registered office located at No.369 South Yuzhou RD., HaiZhou District, Lianyungang, Jiangsu Province, Mainland China (“Licensee”).

SECOND AMENDMENT TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT
Exclusive License and Collaboration Agreement • March 4th, 2021 • Hutchison China MediTech LTD • Pharmaceutical preparations

This Second Amendment (this "Second Amendment") to the Amended and Restated Exclusive License and Collaboration Agreement, effective as of October 8, 2013 and amended by the First Amendment effective as of December 18, 2018 (the "First Amendment"), and made by and between

EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT
Exclusive License and Collaboration Agreement • June 16th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • Pennsylvania

THIS EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) dated as of May 3, 2016 (the “Effective Date”), is entered into between The Trustees of the University of Pennsylvania (“Licensor” or “Penn”), and Audentes Therapeutics, Inc., a Delaware corporation (“Company”), having a place of business located at 101 Montgomery Street, Suite 2650, San Francisco, CA 94104, USA, each a “Party” and collectively “Parties”.

EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT
Exclusive License and Collaboration Agreement • March 30th, 2007 • Intermune Inc • Pharmaceutical preparations • Delaware

This Exclusive License and Collaboration Agreement (this “Agreement”) is executed as of October 16, 2006, (the “Execution Date”) and effective as of the Effective Date and is entered into by and between Hoffmann-La Roche Inc., a New Jersey corporation located at 340 Kingsland Street, Nutley, New Jersey 07110 (“Roche Nutley”), and F.Hoffmann-La Roche Ltd, a Swiss corporation, with its principal office at Grenzacherstrasse 124, CH-4070 Basel, Switzerland (“Roche Basel”; Roche Nutley and Roche Basel are collectively referred to as “Roche”), on the one hand, and InterMune, Inc., a Delaware corporation with its principal place of business at 3280 Bayshore Boulevard, Brisbane, California 94005 (“InterMune”), on the other hand.

EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT
Exclusive License and Collaboration Agreement • March 28th, 2008 • Transition Therapeutics Inc. • Medicinal chemicals & botanical products

This Agreement (the “Agreement”), effective as of March 13th , 2008 (the “Effective Date”), is entered into by and among Waratah Pharmaceuticals Inc., a Canadian corporation, with a place of business at 101 College Street, Suite 220, Toronto, Ontario, M5G 1L7, a wholly owned subsidiary of Transition Therapeutics Inc., (hereinafter collectively referred to as “Transition”) and Eli Lilly and Company, an Indiana corporation with a place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 (“Lilly”). Transition and Lilly may be referred to herein individually as a “Party” or collectively as the “Parties.” Reference to a Party shall be deemed to include that Party’s Affiliates.

EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN AMGEN INC. AND NOVARTIS PHARMA AG
Exclusive License and Collaboration Agreement • July 26th, 2017 • Amgen Inc • Biological products, (no disgnostic substances) • New York

This Exclusive License and Collaboration Agreement (this “Agreement”), effective as of August 28, 2015 (the “Effective Date”), is by and between Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, U.S.A. (“Amgen”), and Novartis Pharma AG, a Swiss company having its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”). Amgen and Novartis are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT between CIDARA THERAPEUTICS, INC. and JANSSEN PHARMACEUTICALS, INC. March 31, 2021
Exclusive License and Collaboration Agreement • May 13th, 2021 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

This Exclusive License and Collaboration Agreement (this “Agreement”), dated as of March 31, 2021 (the “Execution Date”), is entered into by and between Cidara Therapeutics, Inc., a Delaware corporation, having an address of 6310 Nancy Ridge Drive, Suite 101, San Diego, CA 92121 (“Cidara”), and Janssen Pharmaceuticals, Inc., a corporation organized and existing under the laws of Pennsylvania, with its principal business office located at 1125 Trenton-Harbourton Road, Titusville, NJ 08560 (“Janssen”). Cidara and Janssen are each sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

AMENDED AND RESTATED EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT by and among BEIGENE, LTD. and CELGENE CORPORATION and CELGENE SWITZERLAND LLC Originally executed on July 5, 2017, and entered into as of August 31, 2017
Exclusive License and Collaboration Agreement • November 13th, 2017 • BeiGene, Ltd. • Pharmaceutical preparations • New York

This AMENDED AND RESTATED EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is entered into as of August 31, 2017 (the “Amended Execution Date”) and made effective as of the Effective Date (as defined in Section 15.2) by and among BeiGene, Ltd., a corporation organized under the laws of the Cayman Islands (“BeiGene”), and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), with respect to all rights and obligations of Celgene under this Agreement in the United States (subject to Section 14.16), and Celgene Switzerland LLC, a Delaware limited liability company (“Celgene LLC”), with respect to all rights and obligations of Celgene under this Agreement outside of the United States (subject to Section 14.16) (Celgene Corp. and Celgene LLC together, “Celgene”). Celgene and BeiGene are each referred to herein by name or as a “Party” or, collectively, as the “Parties”.

EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT
Exclusive License and Collaboration Agreement • May 11th, 2015 • Oncothyreon Inc. • Services-commercial physical & biological research • New York

THIS EXCLUSIVE AND COLLABORATION LICENSE AGREEMENT (this “Agreement”) dated as of April 16, 2014 (the “Effective Date”), is entered into between Sentinel Oncology Limited (“Licensor”), having a place of business at 23 Cambridge Science Park, Milton Road, Cambridge, United Kingdom CB4 0EY, and Oncothyreon Inc., a Delaware corporation (“Company”), having a place of business at 2601 Fourth Ave., Suite 500, Seattle, WA 98121, USA, each a “Party” and collectively “Parties”.

EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT
Exclusive License and Collaboration Agreement • May 11th, 2021 • Kindred Biosciences, Inc. • Pharmaceutical preparations

This Exclusive License and collaboration Agreement (this “Agreement”) is entered into as of May 5, 2021 (the “Effective Date”) by and between Kindred Biosciences Inc., a Delaware corporation, with its principal place of business at 1555 Bayshore Highway, Suite 200, Burlingame, CA 94010 (“KindredBio”), and Elanco US Inc., a Delaware corporation, with its principal place of business at 2500 Innovation Way, Greenfield, IN 46140 (“Elanco”). KindredBio and Elanco are referred to herein individually as a “Party” and collectively as the “Parties.”

EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT by and between Connect Biopharma HongKong Limited and Simcere Pharmaceutical Co., Ltd.
Exclusive License and Collaboration Agreement • November 21st, 2023 • Connect Biopharma Holdings LTD • Pharmaceutical preparations • Hong Kong

Whereas, Licensor is in Control (as defined below) of certain intellectual property and other rights related to the Licensed Compound (as defined below).

EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT BETWEEN LES LABORATOIRES SERVIER SAS INSTITUT DE RECHERCHES INTERNATIONALES SERVIER SAS AND PFIZER INC.
Exclusive License and Collaboration Agreement • September 17th, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Exclusive License and Collaboration Agreement is entered into as of the 30 day of October, 2015 (the “Signing Date”) by and between Les Laboratoires Servier, a corporation incorporated under the laws of France having a principal place of business at 50 rue Carnot, 92150 Suresnes, France (“LLS”) and Institut de Recherches Internationales Servier, a corporation incorporated under the laws of France having its principal place of business at 50 rue Carnot, 92150 Suresnes, France (“IRIS”) (LLS and IRIS being together referred to as “Servier”), and Pfizer Inc., a Delaware corporation having its principal place of business at 235 E. 42nd Street, New York, New York 10017 (“Pfizer”). Servier and Pfizer are individually referred to herein as a “Party” and collectively, as the “Parties”.

EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT by and between FORTY SEVEN, INC. and ONO PHARMACEUTICAL CO., LTD.
Exclusive License and Collaboration Agreement • November 12th, 2019 • Forty Seven, Inc. • Pharmaceutical preparations • Delaware

This Exclusive License and Collaboration Agreement (this “Agreement”) effective as of July 10, 2019 (the “Effective Date”), is by and between Forty Seven, Inc., a Delaware corporation with an address at 1490 O'Brien Drive, Suite A, Menlo Park, CA 94025, United States (“Forty Seven”), and Ono Pharmaceutical Co., Ltd., a company organized and existing under the laws of Japan, with an address at 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka 541-8564, Japan (“Ono”). Forty Seven and Ono may be referred to herein each as a “Party” and collectively as the “Parties”.

Contract
Exclusive License and Collaboration Agreement • November 10th, 2014 • EPIRUS Biopharmaceuticals, Inc. • Pharmaceutical preparations • England and Wales

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

AutoNDA by SimpleDocs
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT by and between AQUINOX PHARMACEUTICALS (CANADA), INC. and ASTELLAS US LLC
Exclusive License and Collaboration Agreement • August 8th, 2018 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • New York

This EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) effective as of May , 2018 (the “Effective Date”), is by and between Aquinox Pharmaceuticals (Canada) Inc., a corporation organized and existing under the laws of Canada, with an address at 450-887 Great Northern Way, Vancouver, B.C., Canada V5T 4T5 (“Aquinox”) and ASTELLAS US LLC, a company organized and existing under the laws of Illinois, with an address at 1 Astellas Way, Northbrook, Illinois 60062, U.S.A. (“Astellas”). Aquinox and Astellas may be referred to herein each as a “Party” and collectively as the “Parties”.

Time is Money Join Law Insider Premium to draft better contracts faster.